QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=3EF2577BC4DBCBF379A24C4BFE185057;jsessionid=09BABAE375E7CDF154CCD35F7CDDAAE4;jsessionid=F77B1C1F28DBB02026FBFE3E23AFD49E;jsessionid=6CB11A6D01BCD342D958BDB7AA1F1689;jsessionid=9F964A625690853CE79C7623D7943479;jsessionid=246F6BCA9A5FED47C6A1F895E9AE6F1F;jsessionid=55C8832DA99201BBC348EE78ACBB5E38 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=3EF2577BC4DBCBF379A24C4BFE185057;jsessionid=09BABAE375E7CDF154CCD35F7CDDAAE4;jsessionid=F77B1C1F28DBB02026FBFE3E23AFD49E;jsessionid=6CB11A6D01BCD342D958BDB7AA1F1689;jsessionid=9F964A625690853CE79C7623D7943479;jsessionid=246F6BCA9A5FED47C6A1F895E9AE6F1F;jsessionid=55C8832DA99201BBC348EE78ACBB5E38